MedTrace Logo

Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis

NCT05404074 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-06-10

No results posted yet for this study

Summary

The purpose of the study is to evaluate the PK, safety and tolerability of cobitolimod ememas (500mg/50mL) given to participants with active left-sided UC.

Conditions

Interventions

DRUG

Cobitolimod 500mg

Rectal administration

Sponsors & Collaborators

  • InDex Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Johan Levin · InDex Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-22
Primary Completion
2022-10-15
Completion
2022-10-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05404074 on ClinicalTrials.gov